Saturday, September 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 29, 2026

KLA forecasts $4B September-quarter revenue as it lifts 2026 wafer equipment view to low $150B range

View original at seekingalpha.com
KLA forecasts $4B September-quarter revenue as it lifts 2026 wafer equipment view to low $150B range Earnings Call Insights: KLA Corporation (KLAC) Q4 2026 MANAGEMENT VIEW * CEO Richard Wallace said, “For the June quarter, KLA results were strong with revenue, profitability and earnings per share all above the midpoint…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Cash flow from operations was $906 million and free cash flow was $817 million; KLA returned $876 million to shareholders, including $571 million in share repurchases and $305 million in dividends.

    60% confidence
  • Second half of calendar 2026 growth for KLA over the first half is anticipated to be approximately 20%.

    60% confidence
  • Since the March Investor Day, demand signals across AI infrastructure have strengthened materially, visibility continues to improve, and the wafer equipment market outlook continues to expand.

    60% confidence
  • KLA is not very good at forecasting.

    60% confidence
  • Some products have lead times closer to 18 to 24 months, and memory pricing impact likely continues through 2027.

    60% confidence
  • Process control is a very high mix, low volume market where KLA's algorithms and 1,600-1,700 worldwide applications engineers give it an advantage; KLA performs well whenever fair competition is allowed.

    60% confidence
  • Memory pricing headwinds to gross margin were around 100 basis points, and probably a bit more than that.

    60% confidence
  • Advanced packaging process control systems revenue is now expected to grow to approximately $1.1 billion in calendar 2026, up more than 70% year-over-year.

    60% confidence
  • Operating expenses were $682 million, consisting of $399 million in R&D and $283 million in SG&A; operating margin was 43.7%, with incremental operating margin in the quarter at 59%.

    60% confidence
  • KLA ended the quarter with $4.9 billion in total cash, cash equivalents and marketable securities and $5.9 billion of debt.

    60% confidence
  • Memory cost headwinds likely continue through next year but are expected to normalize.

    60% confidence
  • Non-GAAP diluted EPS was $1.05 and GAAP diluted EPS was $1.04, each at the upper end of the respective guidance ranges.

    60% confidence
  • The world needs more advanced logic, and the broadening of demand has been happening as hoped.

    60% confidence
  • Effective June 11, 2026, KLA completed a 10-for-1 stock split.

    60% confidence
  • Competitors have been able to ship into fabs in China that KLA hasn't been able to ship into.

    60% confidence
  • Gross margin of 62.4% was driven by a more favorable services mix than modeled and manufacturing scale, offsetting the challenging memory pricing environment and tariff headwinds.

    60% confidence
  • Momentum is expected to accelerate through the second half of calendar 2026 and significant growth is expected to continue in calendar 2027.

    60% confidence
  • Mix is the biggest factor in KLA's gross margin quarter-to-quarter.

    60% confidence
  • It is confusing why KLA can't raise prices to at least offset memory prices.

    60% confidence
  • KLA is raising its expectation for the wafer equipment market, including advanced packaging, to approximately the low $150 billion range in calendar 2026, up from the prior expectation of $140 billion plus, with significant growth planned for calendar 2027.

    60% confidence
  • Revenue of $3.66 billion was above the midpoint of guidance of $3.575 billion.

    60% confidence
  • KLA does not talk about specific customer engagements, declining to discuss SpaceX.

    60% confidence
  • Long lead time optical components can take 12 to 24 months to put new capacity in place.

    60% confidence
  • There are very few concerns about 2027 because the build-out clearly continues.

    60% confidence
  • June quarter results were strong with revenue, profitability and earnings per share all above the midpoint of guidance.

    60% confidence
  • It's pretty hard to go back to customers after taking orders and start to change prices on those orders.

    60% confidence
  • Services has a long-term target of 13% to 15% growth, with 80% of revenue contract-based, and performance is expected toward the higher end of the range.

    60% confidence
  • Input prices have gone up and KLA has had discussions about how it will help capture some of that value.

    60% confidence
  • September-quarter gross margin is guided to 62.5%, plus or minus 1 percentage point; operating expenses to approximately $690 million; and EPS to $1.16 non-GAAP and $1.14 GAAP, each plus or minus $0.10.

    60% confidence
  • Revenue reached a record $3.66 billion.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com